Skip to main content

Diabetes

Featured Article
“The SGLT2i are an expensive group of drugs in comparison to other goal-directed medical therapies for HfrEF, says Mark Munger, PharmD. “Perhaps this data might assist in formulary decisions and…
“Research indicates that metformin may exert the various clinical effects via different signaling pathways; however, the precise mechanisms have not yet been determined and research is ongoing,” says…

Insights

In this week’s issue of Talking Therapeutics, Dr Jennings explores a new drug approval and what it means for patients with chronic kidney disease.
“The SGLT2i are an expensive group of drugs in comparison to other goal-directed medical therapies for HfrEF, says Mark Munger, PharmD. “Perhaps this data might assist in formulary decisions and oversight use of these medications.”
“Research indicates that metformin may exert the various clinical effects via different signaling pathways; however, the precise mechanisms have not yet been determined and research is ongoing,” says Yvette C. Terrie, BS Pharm, RPh, consultant…
As frontline health care providers, pharmacists are in a pivotal position to act as patient identifiers, patient educators and patient advocates especially for those at risk for or with diabetes.

Interactive Features

Bob Maguire, BioLab Sciences, and Charles Pollak, Red One Medical, discuss their recent partnership and highlight a treatment option for veterans with diabetic foot ulcers, which impacts roughly 75,000 veterans.
Does hepatitis C treatment success improve insulin resistance in patients with diabetes?
Back to Top